Company Overview of Broad Institute of MIT and Harvard
7 Cambridge Center
Cambridge, MA 02142
Key Executives for Broad Institute of MIT and Harvard
President and Founding Director
Associate Member and Director of Stanley Center for Psychiatric Research
Compensation as of Fiscal Year 2013.
Broad Institute of MIT and Harvard Key Developments
Massachusetts General Hospital, the Broad Institute and Amgen Announce Strategic Collaboration to Discover New Drugs for Inflammatory Bowel Disease
Jan 15 14
Massachusetts General Hospital (MGH), the Broad Institute and Amgen announced that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists with expertise in clinical medicine, IBD biology, human genetics, genomic technology and drug discovery to work together to help create a new world of therapeutic options for IBD patients. IBD is well known to run in families, suggesting that genes play a significant role in the development and progression of disease. However, until recently, almost nothing was known about the specific genes and mechanisms that predispose or protect someone from developing the disorder. The MGH-Broad-Amgen collaboration will leverage the shared expertise of its participating scientists and partner institutions to discover and develop novel therapies for IBD. The effort will include collection and analysis of patient DNA samples to identify and further validate genetic targets, biological assays to probe gene function, and subsequent drug discovery and development activities. A joint steering committee will be formed to select and guide projects.
Strategic Alliances Broad Institute Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 09:00 AM
Nov 15 13
Strategic Alliances Broad Institute Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 09:00 AM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States. Speakers: Issi Rozen, Director.
Bayer HealthCare and the Broad Institute Enters into Strategic Alliance to Develop Novel Treatment Options in Cancer Therapy
Sep 11 13
Bayer HealthCare has entered into a strategic alliance with the Broad Institute in Cambridge, Massachusetts in the area of oncogenomics and drug discovery. The company said that goal of this collaboration is to jointly discover and develop therapeutic agents that selectively target cancer genome alterations over a period of five years. Oncogenomics is a promising field of oncology research that identifies and characterizes genes which are associated with cancer. The goal of oncogenomics research is to identify new genes which in a modified (mutated) version stimulate (oncogenes) or lose their ability to suppress (tumor suppressor genes) tumor cell growth. This may provide new insights into cancer diagnosis, predicting clinical outcome of cancers, and new targets for cancer therapies. As part of the collaboration, the Broad Institute will share its oncogenomic expertise. Both parties will explore their compound libraries, and use their screening platforms as well as medicinal chemistry expertise to benefit joint projects. The collaboration will be based on joint decision making and the rights to the research findings are shared equally between the partners. Joint Research and Joint Steering Committees will be established for the initiation and selection of projects and as governance structures. Bayer will have an option for an exclusive license for therapeutic agents at preclinical development stage.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries